A group of scientists at Shanghai Virogin Biotech Co. and Zhujiang Hospital in China designed a new mRNA vaccine that could prevent tumor formation associated with human papillomavirus 16 (HPV16) and also reduce its size if used as a treatment.
Immuno Technologies Inc. and affiliated organizations have published preclinical data on a novel parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease.
